Table 4.
Correlation between clinicopathologic parameters and systemic inflammation markers.
| Parameter | No. | NLR High (>1.76) | PLR High (>159.45) | SII High (>548.95 × 109/L) |
SIRI High (>0.89 × 109/L) |
||||
|---|---|---|---|---|---|---|---|---|---|
| (n = 159) | p | (n = 65) | p | (n = 101) | p | (n = 120) | p | ||
| Age | |||||||||
| ≤55 | 134 | 84 (52.8%) | 0.2970 | 33 (50.8%) | 0.9140 | 53 (52.5%) | 0.5604 | 67 (55.8%) | 0.0964 |
| >55 | 135 | 75 (47.2%) | 32 (49.2%) | 48 (47.5%) | 53 (44.2%) | ||||
| Sex | |||||||||
| Male | 173 | 52 (32.7%) | 0.2195 | 22 (33.9%) | 0.7219 | 32 (31.7%) | 0.2878 | 34 (28.3%) | 0.0239 |
| Female | 96 | 107 (67.3%) | 43 (66.2%) | 69 (68.3%) | 86 (71.7%) | ||||
| Location | |||||||||
| Mobile Tongue | 200 | 116 (73.0%) | 0.5292 | 45 (69.2%) | 0.2779 | 73 (72.3%) | 0.5462 | 84 (70.0%) | 0.1427 |
| Other | 69 | 43 (27.0%) | 20 (30.8%) | 28 (27.7%) | 36 (30.0%) | ||||
| Depth of invasion | |||||||||
| ≤1 cm | 165 | 93 (58.5%) | 0.2489 | 30 (46.2%) | 0.0039 | 55 (54.5%) | 0.0723 | 66 (55.0%) | 0.0554 |
| >1 cm | 104 | 66 (41.5%) | 35 (53.9%) | 46 (45.5%) | 54 (45.0%) | ||||
| Lymphatic invasion | |||||||||
| Absent | 196 | 112 (70.4%) | 0.2828 | 45 (69.2%) | 0.4496 | 65 (64.4%) | 0.015 | 80 (66.7%) | 0.0403 |
| Present | 73 | 47 (29.6%) | 20 (30.8%) | 36 (35.6%) | 40 (33.3%) | ||||
| Vascular invasion | |||||||||
| Absent | 261 | 105 (95.5%) | 0.2783 | 198 (97.1%) | 0.9553 | 99 (98.0%) | 0.7141 | 119 (99.2%) | 0.0789 |
| Present | 8 | 5 (4.6%) | 6 (2.9%) | 2 (2.0%) | 1 (0.8%) | ||||
| Perineural invasion | |||||||||
| Absent | 192 | 85 (77.3%) | 0.0751 | 150 (73.5%) | 0.1662 | 66 (65.3%) | 0.0904 | 74 (63.3%) | 0.0090 |
| Present | 77 | 25 (22.7%) | 54 (26.5%) | 35 (34.7%) | 44 (36.7%) | ||||
| T stage | |||||||||
| T1 and T2 | 155 | 88 (55.4%) | 0.3640 | 27 (41.5%) | 0.0026 | 52 (51.5%) | 0.1143 | 62 (51.7%) | 0.0761 |
| T3 and T4 | 114 | 71 (44.7%) | 38 (58.5%) | 49 (48.5%) | 58 (48.3%) | ||||
| Lymph node metastasis | |||||||||
| Absent | 176 | 75 (68.2%) | 0.4295 | 40 (61.5%) | 0.4490 | 60 (59.4%) | 0.1074 | 72 (60.0%) | 0.0930 |
| Present | 93 | 35 (31.8%) | 25 (38.5%) | 41 (40.6%) | 47 (40.0%) | ||||
| Stage | |||||||||
| I, II | 128 | 69 (43.4%) | 0.0983 | 22 (33.9%) | 0.0109 | 37 (36.6%) | 0.0053 | 47 (39.2%) | 0.0131 |
| III, IV | 141 | 90 (56.0%) | 43 (66.2%) | 64 (63.4%) | 73 (60.8%) | ||||
| Distant metastasis | |||||||||
| Absent | 254 | 152 (95.6%) | 0.3132 | 60 (92.3%) | 0.3932 | 95 (94.1%) | 0.8400 | 115 (95.8%) | 0.3659 |
| Present | 15 | 7 (4.4%) | 5 (7.7%) | 6 (5.9%) | 5 (4.2%) | ||||
NLR, neutrophil–lymphocyte ratio; PLR, platelet–lymphocyte ratio; SII, systemic inflammation index; SIRI, systemic inflammation response index.